Ipsen’s First Quarter 2013 Sales
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Regulatory News:
Commenting on the first quarter 2013 performance, Marc de Garidel, Chairman and Chief Executive Officer of Ipsen said: “Ipsen is off to a good start this year with a solid specialty care growth, up 8.0%, notably driven by the good performance of Somatuline®. Moreover, primary care proved resilient with strong growth of Smecta® sales and international sales.” Marc de Garidel added : “Despite supply shortage issues with Increlex®, Ipsen confirms its 2013 guidance, both in terms of sales and recurring adjusted3 operating margin.”
Help employers find you! Check out all the jobs and post your resume.
Regulatory News:
Commenting on the first quarter 2013 performance, Marc de Garidel, Chairman and Chief Executive Officer of Ipsen said: “Ipsen is off to a good start this year with a solid specialty care growth, up 8.0%, notably driven by the good performance of Somatuline®. Moreover, primary care proved resilient with strong growth of Smecta® sales and international sales.” Marc de Garidel added : “Despite supply shortage issues with Increlex®, Ipsen confirms its 2013 guidance, both in terms of sales and recurring adjusted3 operating margin.”
Help employers find you! Check out all the jobs and post your resume.